NUVALENT, INC.
NUVALENT, INC. is a biotechnology company focused on developing novel treatments for cancer.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Nuvalent's stock with a target price of $115.15, indicating strong growth potential.
Financial Health
Nuvalent, Inc. has strong cash flow and a solid book value per share, indicating good financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring NUVL
Targeting Superbugs: The Next Wave Of Antibiotics
GSK's new antibiotic for gonorrhea has received priority review from the FDA, underscoring the urgent need for new antimicrobial treatments. This event signals a potential resurgence in the market for companies developing novel antibiotics to address drug-resistant infections.
Published: August 11, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Precision oncology focus
Develops targeted small‑molecule programmes against specific genetic drivers; scientific progress can attract partners, though trials carry inherent risk.
Catalysts to watch
Upcoming clinical readouts, regulatory milestones and collaboration announcements can move the stock significantly, but outcomes are uncertain.
Funding and partnerships
Partnerships may de‑risk programmes and add resources, while additional financing could dilute shareholders — both materially affect prospects.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
